In vivo administration of EGF, HB-EGF, or neuroegulin-1 elevates the concentrations of dopamine and its metabolite, 4-dihydroxyphenylacetic acid (DOPAC), in the striatum of Parkinson’s model animals [97,103,113] as well as in normal rats [114]. This evidence concerns the gene EGF and Parkinson disease.